KR20080068147A - 암 치료의 효능을 증진시키는 방법 - Google Patents

암 치료의 효능을 증진시키는 방법 Download PDF

Info

Publication number
KR20080068147A
KR20080068147A KR1020087015948A KR20087015948A KR20080068147A KR 20080068147 A KR20080068147 A KR 20080068147A KR 1020087015948 A KR1020087015948 A KR 1020087015948A KR 20087015948 A KR20087015948 A KR 20087015948A KR 20080068147 A KR20080068147 A KR 20080068147A
Authority
KR
South Korea
Prior art keywords
cells
tumor
antibody
human
wnt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087015948A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 타이스
다이앤 페니카
폴 폴라키스
웨인 스제토
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/759,056 external-priority patent/US7173115B2/en
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20080068147A publication Critical patent/KR20080068147A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
KR1020087015948A 2000-08-29 2001-07-10 암 치료의 효능을 증진시키는 방법 Ceased KR20080068147A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US22891400P 2000-08-29 2000-08-29
US60/228,914 2000-08-29
US09/759,056 US7173115B2 (en) 2000-01-13 2001-01-11 Stra6 polypeptides
US09/759,056 2001-01-11
US09/901,812 2001-07-10
US09/901,812 US20020173461A1 (en) 2000-01-13 2001-07-10 Methods for enhancing the efficacy of cancer therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020037002956A Division KR100865801B1 (ko) 2000-08-29 2001-07-10 암 치료의 효능을 증진시키는 방법

Publications (1)

Publication Number Publication Date
KR20080068147A true KR20080068147A (ko) 2008-07-22

Family

ID=27397886

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087015948A Ceased KR20080068147A (ko) 2000-08-29 2001-07-10 암 치료의 효능을 증진시키는 방법

Country Status (10)

Country Link
EP (2) EP1341923A2 (https=)
JP (1) JP2004507251A (https=)
KR (1) KR20080068147A (https=)
AT (1) ATE453718T1 (https=)
AU (1) AU2001271938A1 (https=)
CA (1) CA2420867C (https=)
DE (1) DE60140966D1 (https=)
ES (1) ES2337696T3 (https=)
NZ (1) NZ524230A (https=)
WO (1) WO2002018608A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004519250A (ja) * 2000-03-23 2004-07-02 キュラゲン　コーポレイション 新規ヒトｓｔｒａ６様タンパク質およびこれをコードする核酸
CA2481239A1 (en) * 2002-04-05 2003-10-23 University Of Utah Research Foundation Regulation of a novel colon specific retinol dehydrogenase by apc and cdx2
WO2003090686A2 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
EP1833970A2 (en) * 2004-12-22 2007-09-19 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
TWI407971B (zh) * 2007-03-30 2013-09-11 日東電工股份有限公司 Cancer cells and tumor-related fibroblasts
SI2710035T1 (sl) 2011-05-16 2017-07-31 F. Hoffmann-La Roche Ag Agonisti FGFR1 in tehnike njihove uporabe
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
CN114574378B (zh) * 2022-04-11 2023-09-22 浙江大学 一种生产视黄酸的基因工程菌及其构建方法和应用
CN117625626B (zh) * 2024-01-25 2024-04-16 中国农业科学院植物保护研究所 RNAi在提高苏云金芽胞杆菌杀虫蛋白防治二化螟或草地贪夜蛾效果中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997852A (en) * 1987-08-26 1991-03-05 Ohio State University Research Foundation Method and composition for achieving cancer chemopreventive and chemotherapeutic activity
US5731167A (en) * 1992-01-17 1998-03-24 The United States Of America As Represented By The Department Of Health And Human Services Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy
AU2582897A (en) 1996-03-15 1997-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
CA2397207C (en) * 2000-01-13 2013-12-03 Genentech, Inc. Novel stra6 polypeptides

Also Published As

Publication number Publication date
WO2002018608A3 (en) 2003-06-26
WO2002018608A9 (en) 2003-08-07
WO2002018608A2 (en) 2002-03-07
JP2004507251A (ja) 2004-03-11
CA2420867C (en) 2013-02-05
CA2420867A1 (en) 2002-03-07
EP1341923A2 (en) 2003-09-10
EP1666600B1 (en) 2009-12-30
EP1666600A1 (en) 2006-06-07
AU2001271938A1 (en) 2002-03-13
ES2337696T3 (es) 2010-04-28
DE60140966D1 (de) 2010-02-11
ATE453718T1 (de) 2010-01-15
NZ524230A (en) 2006-05-26

Similar Documents

Publication Publication Date Title
EP1626084B1 (en) Compositions and methods for the diagnosis of tumours
JP5701624B2 (ja) 新規なｓｔｒａ６ポリペプチド
US20050176104A1 (en) Compositions and methods for the treatment of tumor
JP2009039097A (ja) 腫瘍治療のための組成物及び方法
JP2006006332A (ja) 腫瘍の治療のための組成物と方法
EP1666600B1 (en) Methods for enhancing the efficacy of cancer therapy
KR20010103576A (ko) 종양 치료용 조성물 및 치료 방법
KR20010102960A (ko) 종양 치료용 조성물 및 방법
KR100865801B1 (ko) 암 치료의 효능을 증진시키는 방법
AU2007203291B2 (en) Methods for enhancing the efficacy of cancer therapy
DE60032395T2 (de) Methode zum Nachweis von Tumoren

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20080630

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080730

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20081014

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20081218

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20081014

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I